Our Scans · Cannabis · Weekly Summary

• While risks remain substantial, particularly around regulatory timelines and sector volatility, Trulieve appears better positioned than many peers to capitalize on a more favorable operating environment should cannabis reform continue advancing throughout 2026. Kalkine
• The growing medical use of cannabis was reduced by U.S. political developments and racialized anti-cannabis propaganda, which portrayed it as a drug of abuse and threatened the hemp industry. PubMed Central (PMC)
• Total U.S. legal marijuana revenue is expected to reach $30.5 billion in 2026, up 4.9% from 2025. The Marijuana Herald
• Alabama becomes the fortieth US state where medical cannabis is legally accessible, with three further dispensary companies expected to open additional sites by summer 2026. Business of Cannabis
• BUSINESS TerrAscend Corp. announced preliminary expected quarterly net revenue of $65.5 million, Canadian retailers sold C$ 440.5 million worth of legal cannabis products in February. Marijuana Moment
• Schedule III brings cannabis into the fold of federal regulation, which means the FDA will likely take a more active role in product safety and labeling. Goldleaf
• American cannabis companies may soon be able to export products to international markets, while foreign pharmaceutical companies will invest in U.S. cannabis research and development. Secret Nature
• The Department of Justice announced it will place FDA-approved and state-regulated medical marijuana products into Schedule III, a move that recognizes their medical use while maintaining federal oversight. OpenLoop Health, Inc.
• The IRS plans to offer tax guidance for state-legal medical cannabis companies. The Blunt Truth
• The cannabis industry is expected to contribute more than $123 billion in economic impact in 2025, and that momentum is carrying forward into 2026, creating opportunities for stores that can adapt to consumer behaviour. Marijuana Business Conference & Expo

Last updated: 08 July 2026